
The mRNA pioneer with BioNTech researcher Jason Keller at a conference.
Continuation from part 3
She could have stopped everything. At the end of 2012, biochemist Katalin Karikó, then 57, was unexpectedly let go by the University of Pennsylvania. The university told her that her research would not attract new sponsors and, despite her 23 years of loyal service, they no longer wished to employ her.
It was an incredibly bitter blow for Karikó, who at that time had great ambitions. She had only recently discovered how to modify mRNA so that the lab-made molecule would not trigger inflammation in the body. Now she wanted to continue her research until the very first mRNA-based therapy for humans became a reality—a goal she had been working toward for decades.
But in the U.S., a researcher of her age had virtually no opportunities left. Besides, Karikó already had everything most people dream of: a small house, a loving husband, and a daughter who had just become a two-time Olympic rowing champion—the perfect setting for a peaceful retirement.
For the First Time, She Becomes a Boss
Yet Karikó couldn’t walk away from science. She began looking for ways to continue her research in Europe. Soon, she received an offer from Uğur Şahin, founder of the German company BioNTech, to join his firm in Mainz as Senior Vice President. Karikó accepted, even though it meant leaving her family behind and moving alone to Germany without speaking the language. She would later describe this as «the hardest moment of my life.»
Settling in was tough. She was plagued by homesickness. «During the first week, I cried myself to sleep every night, thinking I had made a huge mistake. But after that week, I became so busy that I just fell asleep and didn’t have time to cry anymore,» she once told this newspaper in an interview . Over time, things improved—thanks to her work. For the first time in her life, Karikó was in a leadership role and could build her own team. One of her first hires was German researcher Azita Mahiny.
Together with Mahiny and other team members, Karikó worked on further optimizing mRNA sequences to boost protein production. It was no easy task. In 2014, mRNA vaccines were known only to experts, and hardly anyone was thinking about the possibility of a global pandemic. Still, BioNTech’s research in Mainz flourished.
Article series
Miracle Molecule mRNA – Katalin Karikó’s Legacy
No other method holds as much potential to revolutionize medicine as mRNA technology. The mRNA research, significantly shaped by the Hungarian-American biochemist Katalin Karikó, has doctors dreaming of curing infectious diseases, genetic disorders, and cancer within the coming years. In this series, we highlight projects by leading researchers who, building on Karikó’s work, are introducing mRNA technology into various fields of medicine.
«That was mainly because the team worked so well together,» recalls Mahiny. The Berlin native came from a completely different background than Karikó. After her studies in Berlin, she briefly worked as a marine biologist in Australia before returning to Germany and switching to immunology. Karikó, in contrast, had spent decades diving deep into the intricacies of the immune system. Their personalities also differed. «Kati is extremely structured and focused—her brain works in Excel spreadsheets. I, on the other hand, have a more creative streak,»
Mahiny says, looking back.

mRNA-researcher Azita Mahiny
A Positive Team Culture Was Key to Success
Sometimes, their differences led to quirky situations. «One evening, I sent Kati data from an experiment and then left for an orchestra rehearsal. But she couldn’t open the file. Waiting until the next morning? Unthinkable for Kati. So, I went back and re-saved it—otherwise, she probably wouldn’t have slept that night,» Mahiny recalls. This episode illustrates how driven Karikó is. When she wants to figure something out, no effort is too great.
This view is shared by Jason Keller, an American scientist who had known Karikó since her time at the University of Pennsylvania. Keller initially worked alongside her in Philadelphia before moving to a U.S. National Institutes of Health lab and later to the Netherlands. When Karikó finally got the chance to build her own team at BioNTech, she brought Keller back on board.
«What I appreciated most about Kate was how she included us in her personal life. I knew her husband Béla—always tinkering with engines or the house—and her daughter Susan,» Keller says. Karikó even changed his life in another, unexpected way: she introduced him to Sandra, the woman who would later become his wife.
At BioNTech, the staff became more than just colleagues. Under Karikó’s leadership, friendships formed that extended well beyond the workplace. «The team she built has stayed intact to this day, with no turnover,»
Mahiny explains. «Kati recognizes people’s strengths and places them where they can excel—that’s what makes the team so successful.»
Decades of Preparation Make It Possible to End a Pandemic
When the COVID-19 pandemic brought the world to a standstill in 2020, BioNTech was one of the companies best prepared to respond, thanks to years of cutting-edge research and a talented group of scientists, including Karikó, Şahin, and Özlem Türeci. After working tirelessly to develop a vaccine, BioNTech became the first company to receive emergency use authorization in the U.S. on December 11, 2020—a milestone step toward ending the pandemic.
What followed in Karikó’s life was like the final act of an action movie. For the first time, her work was recognized worldwide. Suddenly, she was in front of cameras from major global TV networks. Almost every newspaper reported on her life story.
She received hundreds of prestigious scientific awards—including several from Switzerland—and ultimately crowned her career by winning the 2023 Nobel Prize in Medicine. But anyone who thinks this tireless scientist retired after all the chaos is mistaken. Karikó was already working on a plan to share her success with young researchers, aiming to ensure that others wouldn’t face the same obstacles she had encountered throughout her career ...
Find the fifth and final part of the series here .
Note
* This article series has been nominated for the Prix Média Newcomer 2025 and was supported by the Swiss Academy of Sciences.





